Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
Jan 9, 2009
|
9.2 KB
|
| |
SOUTH SAN FRANCISCO, Jan 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc.
(Nasdaq: ANSV) today announced that the U.S. Food and Drug Administration
(FDA) has approved Anesiva's supplemental New Drug Application (sNDA) to
expand the indication for Zingo(TM) to treat the pain associated with blood
draws to include adults. ...
|
|
|
Anesiva Announces Changes to Its Board of Directors and Receives Notification From Nasdaq
Dec 19, 2008
|
10.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva,
Inc. (Nasdaq: ANSV), a specialty pain management company, announced today that
consistent with its recent announcement of a positive Phase 3 clinical trial
for Adlea(TM) and to focus on this asset by going to a virtual company model,
five member...
|
|
|
Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
Dec 16, 2008
|
12.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva,
Inc. (Nasdaq: ANSV) today announced top-line results showing that the Phase 3
trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug
candidate, achieved its primary efficacy endpoint of reducing post-surgical
pain versus placebo ...
|
|
|
Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
Nov 10, 2008
|
13.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the ACTIVE-1 Phase 3 trial evaluating Adlea(TM), a novel formulation of capsaicin, narrowly missed its primary endpoint of reducing post-surgical pain versus placebo (p=0.07) following bunionectomy surgery at...
|
|
|
Anesiva Secures Financing for Up to $30 Million
Oct 2, 2008
|
13.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV), a specialty pharmaceutical company focused on pain management, announced that it has successfully secured a term loan for up to $30 million. The financing was led by Oxford Finance Corporation, and was co-funded by CIT Healthcar...
|
|
|
Click here to download our most recent fact sheet.